Baader Bank Aktiengesellschaft Grows Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• Baader Bank Aktiengesellschaft increased its position in BioNTech SE by 6.3% during Q2, owning 151,862 shares valued at approximately $16 million.
• BioNTech reported a quarter EPS of ($1.60), missing estimates, but achieved a revenue of $306.46 million, significantly exceeding expectations.
• Wall Street analysts maintain a positive outlook on BioNTech, with a consensus target price of $135.22 and many analysts rating it a "buy."

Baader Bank Aktiengesellschaft raised its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 6.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 151,862 shares of the company's stock after acquiring an additional 9,040 shares during the quarter. BioNTech makes up 1.1% of Baader Bank Aktiengesellschaft's investment portfolio, making the stock its 13th largest position. Baader Bank Aktiengesellschaft owned 0.06% of BioNTech worth $16,032,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets increased its position in shares of BioNTech by 94.6% in the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock valued at $108,859,000 after acquiring an additional 581,173 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of BioNTech by 18,892.9% during the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock valued at $63,593,000 after purchasing an additional 694,691 shares in the last quarter. Invesco Ltd. boosted its stake in shares of BioNTech by 643.7% during the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company's stock valued at $58,747,000 after purchasing an additional 558,389 shares in the last quarter. Millennium Management LLC boosted its stake in shares of BioNTech by 252.5% during the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company's stock valued at $49,625,000 after purchasing an additional 390,360 shares in the last quarter. Finally, LBP AM SA boosted its stake in shares of BioNTech by 20.7% during the 1st quarter. LBP AM SA now owns 305,221 shares of the company's stock valued at $27,793,000 after purchasing an additional 52,303 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Up 2.6%

Shares of NASDAQ BNTX traded up $2.50 during midday trading on Monday, hitting $98.72. The stock had a trading volume of 741,522 shares, compared to its average volume of 1,323,409. The business's 50 day moving average is $107.10 and its 200-day moving average is $103.31. The company has a market cap of $23.73 billion, a P/E ratio of -61.70 and a beta of 1.39. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The firm had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company's quarterly revenue was up 102.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analyst Ratings Changes

BNTX has been the topic of a number of research reports. Leerink Partners set a $112.00 target price on shares of BioNTech in a research note on Monday, June 2nd. The Goldman Sachs Group initiated coverage on shares of BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 target price on the stock. Bank of America lifted their target price on shares of BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. boosted their price objective on shares of BioNTech from $116.00 to $121.00 and gave the stock a "neutral" rating in a research note on Monday. Finally, HC Wainwright reissued a "buy" rating and set a $136.00 price objective on shares of BioNTech in a research note on Monday, September 8th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $134.56.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.